CytoDyn Inc.

CYDY

CytoDyn Inc.

CYDY

Insider Sentiment (TTM):

Last Purchase:2020-11-02Last Sale:2020-12-22Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:299,779Shares Outstanding:1,275,184,000Institutional Ownership Pct.:0.02%

Earnings Market Reaction:

Filing Date:2026-04-08Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-02-28	2025-11-30	2025-08-31	2025-05-31	2025-02-28	2024-11-30	2024-08-31	2024-05-31	2024-02-29	2023-11-30	2023-08-31	2023-05-31
Series B Preferred Stock	0	0	0	0	0	0	0	0	0	0	0	0
Series C Preferred Stock	0	0	0	0	0	0	0	0	0	0	0	0
Series D Preferred Stock	0	0	0	0	0	0	0	0	0	0	0	0
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	16	5	9	12	16	21	25	3	1	0	2	3
Restricted Cash And Cash Equivalents At Carrying V…	-	-	-	0	0	0	0	7	7	7	7	7
Prepaid Expense Current	0	1	1	0	1	1	1	0	1	2	3	1
Accounts And Other Receivables Net Current	-	-	-	2	2	2	2	-	-	-	-	-
Assets Current	18	9	13	18	21	25	28	11	10	9	12	11
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	18	9	13	18	21	25	28	11	10	9	12	11
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	13	14	14	15	15	14	14	30	62	62	63	63
Interest Payable Current	12	15	17	18	19	18	16	15	14	13	12	11
Dividends Payable Current	9	9	9	8	8	8	7	7	6	6	6	5
Convertible Debt Current	-	27	27	27	27	29	29	30	30	33	33	34
Derivative Liabilities Current	-	-	-	-	-	-	-	-	3	0	4	0
Liabilities Current	50	85	69	71	71	71	70	84	129	123	129	120
Liabilities Noncurrent
Notes Payable	-	-	-	-	-	-	-	-	-	-	-	1
Operating Lease Liability Noncurrent	-	-	-	0	0	0	0	0	0	0	0	0
Convertible Debt Noncurrent	27	-	-	-	-	-	-	-	-	-	-	-
Other Liabilities Noncurrent	44	44	44	44	44	44	44	44	-	-	-	-
Liabilities	123	129	113	114	114	114	113	128	130	124	129	121
Stockholders Equity
Common Stock Value	1	1	1	1	1	1	1	1	1	1	1	1
Additional Paid In Capital	815	795	793	790	788	786	786	774	754	747	735	731
Retained Earnings Accumulated Deficit	-921	-916	-893	-888	-882	-877	-872	-892	-875	-863	-853	-842
Stockholders Equity	-104	-120	-100	-96	-93	-89	-85	-117	-119	-114	-117	-110
Liabilities And Stockholders Equity	18	9	13	18	21	25	28	11	10	9	12	11
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	-	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	2,250	2,250	1,750	1,750	1,750	1,750	1,750	1,750	1,750	1,750	1,350	1,750
Common Stock Shares Issued	1,358	1,266	1,257	1,249	1,233	1,224	1,220	1,059	990	972	931	919
Shares Outstanding	1,358	1,266	1,257	1,249	1,232	1,223	1,220	1,059	990	971	931	919
Treasury Stock Common Shares	0	0	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-11.11%	22.22%	3.70%	-11.11%	-7.41%	-3.70%	10.71%	7.14%	-10.71%	-	-	-
2025	-14.29%	-21.43%	-14.29%	40.00%	73.33%	40.00%	100.00%	75.00%	40.00%	-6.67%	-3.33%	-10.00%
2024	5.88%	64.71%	23.53%	-15.00%	-5.00%	-15.00%	7.14%	7.14%	0.00%	25.00%	25.00%	8.33%
2023	-	-	-	-	-	-	-18.18%	-21.21%	-18.18%	-10.00%	-20.00%	5.00%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-02-28	2025-11-30	2025-08-31	2025-05-31	2025-02-28	2024-11-30	2024-08-31	2024-05-31	2024-02-29	2023-11-30	2023-08-31	2023-05-31
Liquidity Ratios
Current Ratio	0.37	0.10	0.19	0.25	0.30	0.35	0.40	0.13	0.08	0.07	0.09	0.09
Quick Ratio	0.36	0.10	0.18	0.25	0.29	0.34	0.39	0.12	0.07	0.06	0.07	0.08
Working Capital	-31.99M	-76.27M	-56.07M	-52.64M	-49.58M	-45.99M	-41.82M	-73.37M	-119.57M	-114.57M	-117.09M	-108.99M
Leverage & Debt
Debt to Equity	-1.18	-1.07	-1.14	-1.19	-1.23	-1.28	-1.33	-1.10	-1.09	-1.08	-1.11	-1.10
Interest Coverage TTM	-	-	-	-	0.80	0.47	0.36	-0.57	-0.42	-0.42	-1.02	-1.03
Debt Ratio	6.64	14.40	8.38	6.32	5.39	4.59	4.04	11.48	12.62	13.38	10.42	10.70
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.03	-0.03	-0.02	0.00	-0.01	-0.01	-0.02	-0.05	-0.05	-0.06	-0.08	-0.10
Free Cash Flow Per Share TTM	-0.01	-0.01	-0.01	-0.01	-0.00	-0.00	-0.00	-0.01	-0.01	-0.02	-0.02	-0.03
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%
Net Income Growth (1Y)	447.46%	172.75%	10.39%	-107.51%	-86.29%	-73.35%	-72.95%	-37.56%	-64.43%	-69.07%	-62.24%	-62.14%
EPS Growth (1Y)	427.31%	164.18%	0.04%	-106.04%	-89.04%	-79.08%	-77.99%	-46.13%	-69.86%	-73.77%	-67.79%	-69.36%
Valuation Metrics
P/E TTM	-8.22	-10.71	-17.87	109.47	-53.73	-9.43	-8.94	-3.11	-4.94	-3.05	-2.75	-2.72
P/B TTM	-3.06	-3.48	-3.78	-4.27	-4.10	-1.50	-2.00	-1.33	-2.14	-1.43	-1.66	-1.99
Market Cap	318.80M	416.14M	375.77M	409.96M	380.76M	134.35M	170.26M	155.12M	255.37M	163.03M	193.95M	217.50M
Enterprise Value	330.34M	438.35M	393.63M	425.25M	391.50M	141.55M	174.25M	175.10M	277.52M	189.22M	218.48M	250.09M
Calculated Values
Free Cash Flow TTM	-17.98M	-17.42M	-16.66M	-8.77M	-4.75M	-2.13M	-1.05M	-10.98M	-12.74M	-16.63M	-18.53M	-25.11M
Net Debt	11.55M	22.22M	17.87M	15.30M	10.74M	7.20M	4.00M	19.98M	22.15M	26.19M	24.53M	32.59M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2020-12-22Sale

Owner: Mulholland, Michael D.

Title: Chief Financial Officer

Shares: 711,801

Price/Share: $6.37

Value: $4,534,172.37

Shares Owned: 284,081

Relationship: Officer

Ownership: Direct

2020-12-21Sale

Owner: Mulholland, Michael D.

Title: Chief Financial Officer

Shares: 585,797

Price/Share: $5.58

Value: $3,268,747.26

Shares Owned: 284,081

Relationship: Officer

Ownership: Direct

2020-11-02Purchase

Owner: Naydenov, Jordan G

Title: -

Shares: 193,500

Price/Share: $2.57

Value: $497,295.00

Shares Owned: 6,451,323

Relationship: Director

Ownership: Direct

2020-10-23Purchase

Owner: Naydenov, Jordan G

Title: -

Shares: 120,000

Price/Share: $2.49

Value: $298,800.00

Shares Owned: 6,257,823

Relationship: Director

Ownership: Direct

2020-10-23Purchase

Owner: Colachis, Arian

Title: GC and Corporate Secretary

Shares: 10,000

Price/Share: $2.50

Value: $25,000.00

Shares Owned: 80,000

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2020-12-22	Mulholland, Michael D.	Officer	Chief Financial Officer	Direct	Sale	711,801	6.37	$4,534,172.37	284,081	4
2020-12-21	Mulholland, Michael D.	Officer	Chief Financial Officer	Direct	Sale	585,797	5.58	$3,268,747.26	284,081	4/A
2020-11-02	Naydenov, Jordan G	Director	-	Direct	Purchase	193,500	2.57	$497,295.00	6,451,323	4
2020-10-23	Naydenov, Jordan G	Director	-	Direct	Purchase	120,000	2.49	$298,800.00	6,257,823	4
2020-10-23	Colachis, Arian	Officer	GC and Corporate Secretary	Direct	Purchase	10,000	2.50	$25,000.00	80,000	4
2020-05-04	Pourhassan, Nader	Director,Officer	President & CEO	Direct	Sale	1,201,652	2.79	$3,352,609.08	908,343	4
2020-05-01	Kelly, Scott A.	Director,Officer	Chief Medical Officer	Direct	Sale	1,200,000	3.26	$3,912,000.00	1,557,718	4
2020-05-01	Kelly, Scott A.	Director,Officer	Chairman & CMO	Direct	Sale	1,200,000	3.26	$3,912,000.00	1,557,718	4/A
2020-05-01	Kelly, Scott A.	Director,Officer	Chief Medical Officer	Direct	Purchase	250,000	0.57	$142,500.00	1,847,302	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

0.02%

Inst. Shares: 299,779

Shares Outstanding: 1,275,184,000

2025-12-31

0.03%

Inst. Shares: 351,779

Shares Outstanding: 1,261,016,000

2025-09-30

0.03%

Inst. Shares: 366,779

Shares Outstanding: 1,252,551,000

2025-06-30

0.02%

Inst. Shares: 262,186

Shares Outstanding: 1,205,755,000

2025-03-31

0.02%

Inst. Shares: 248,233

Shares Outstanding: 1,228,259,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	299,779	1,275,184,000	0.02%
2025-12-31	351,779	1,261,016,000	0.03%
2025-09-30	366,779	1,252,551,000	0.03%
2025-06-30	262,186	1,205,755,000	0.02%
2025-03-31	248,233	1,228,259,000	0.02%
2024-12-31	253,229	1,221,405,000	0.02%
2024-09-30	221,717	1,135,043,000	0.02%
2024-06-30	242,830	969,509,000	0.03%
2024-03-31	269,329	982,209,000	0.03%
2023-12-31	211,235	958,988,000	0.02%
2023-09-30	196,481	923,587,000	0.02%
2023-06-30	534,710	836,528,000	0.06%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

CytoDyn Inc. (CYDY) — SEC Financial Statements & Analysis

CytoDyn Inc. (CYDY) is a pharmaceutical preparations company, incorporated in DE. CytoDyn Inc. trades on OTC as: CYDY. Based on its latest SEC filing (Form 10-Q, period ending 2026-02-28), CytoDyn Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of -1.18x, a Price-to-Book (P/B) ratio of -3.06x (TTM), at a market cap of $318.80M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: -1.18x
P/B TTM: -3.06x
Market Cap: $318.80M

Data as of 2026-02-28 · Source: SEC EDGAR

Frequently Asked Questions

What industry is CytoDyn Inc. in?

CytoDyn Inc. (CYDY) operates in the Pharmaceutical Preparations industry.

What is CYDY's market cap?

CytoDyn Inc. (CYDY) has a market capitalization of $318.80M as of 2026-02-28.

What exchange does CYDY trade on?

CytoDyn Inc. (CYDY) trades on the OTC.

Where is CytoDyn Inc. incorporated?

CytoDyn Inc. is incorporated in DE.

CytoDyn Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

CytoDyn Inc. (CYDY) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

CytoDyn Inc. (CYDY) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.